Adding pembrolizumab before and after surgery reduced recurrence and improved response in patients with locally advanced head ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Pembrolizumab (Keytruda), an anti-PD-1 antibody, cleared minimal residual disease and protected against recurrence in ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Can ctDNA-guided therapy stop cancer’s return, sparing patients unnecessary treatment? A new study suggests it might.

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Pembrolizumab alone or in combination with chemotherapy can provide long-term benefits over chemotherapy alone in recurrent or metastatic HNSCC, data suggest.

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the potential of pembrolizumab (Keytruda; Merck) to improve outcomes following head and neck ...

FDA meeting requested following Phase IIb trial showing median overall survival of 17.6 months without chemotherapy Immutep ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...